Literature DB >> 12861488

Nasal breathing and continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea (OSA).

Jan H Hollandt1, Malte Mahlerwein.   

Abstract

Although nasal continuous positive airway pressure (nCPAP) treatment is the most efficient therapy for obstructive sleep apnea (OSA), compliance with therapy is poor because of several side effects. Among these adverse effects some are related to the reactions of the nose to nCPAP which are briefly described. In a long-term survey of 109 OSA patients, 80.6% continued nCPAP for at least 3 years until the last follow-up. Follow-up ranged between 0.8 and 109 months with a mean time of 43 (SD +/- 24.7) months. Among all patients treated with nCPAP, only 46.6% met our criteria for long-term compliance, defined as a mean use of the CPAP machine for at least 5 hours per night. Within the objective measures such as age, body mass index, neck circumference, nasal airflow, apnea-hypopnea index, minimal oxygen saturation, and level of nCPAP pressure, no predictive factor for daily use of nCPAP could be found. However, pretherapeutic daytime somnolence (measured by visual analogue scale and Epworth Sleepiness Scale) and its improvement obtained from the therapy showed a significant effect on the daily use of the CPAP machine.

Entities:  

Mesh:

Year:  2003        PMID: 12861488     DOI: 10.1007/s11325-003-0087-7

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  42 in total

1.  Effects of humidification on nasal symptoms and compliance in sleep apnea patients using continuous positive airway pressure.

Authors:  C A Massie; R W Hart; K Peralez; G N Richards
Journal:  Chest       Date:  1999-08       Impact factor: 9.410

2.  Dangerous hypoxaemia during continuous positive airway pressure treatment of obstructive sleep apnoea.

Authors:  J Krieger; E Weitzenblum; J P Monassier; C Stoeckel; D Kurtz
Journal:  Lancet       Date:  1983-12-17       Impact factor: 79.321

Review 3.  Sleep-related breathing disorders. 5. Nasal continuous positive airway pressure treatment for obstructive sleep apnoea.

Authors:  R R Grunstein
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

Review 4.  [CPAP therapy in obstructive sleep apnea syndrome. Side effects and acceptance in long-term follow-up].

Authors:  K Rasche; M Orth; H W Duchna; H U Ullrich; G Schultze-Werninghaus
Journal:  Med Klin (Munich)       Date:  1994-02-15

5.  Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial.

Authors:  C Jenkinson; R J Davies; R Mullins; J R Stradling
Journal:  Lancet       Date:  1999-06-19       Impact factor: 79.321

6.  Treatment of obstructive sleep apnea with nasal continuous positive airway pressure. Patient compliance, perception of benefits, and side effects.

Authors:  V Hoffstein; S Viner; S Mateika; J Conway
Journal:  Am Rev Respir Dis       Date:  1992-04

7.  [Postoperative management following rhinosurgery interventions in severe obstructive sleep apnea. A pilot study].

Authors:  M Dorn; W Pirsig; T Verse
Journal:  HNO       Date:  2001-08       Impact factor: 1.284

8.  Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares.

Authors:  C E Sullivan; F G Issa; M Berthon-Jones; L Eves
Journal:  Lancet       Date:  1981-04-18       Impact factor: 79.321

9.  Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement.

Authors:  A G Togias; R M Naclerio; D Proud; J E Fish; N F Adkinson; A Kagey-Sobotka; P S Norman; L M Lichtenstein
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

10.  Side effects of nasal continuous positive airway pressure in sleep apnea syndrome. Study of 193 patients in two French sleep centers.

Authors:  J L Pépin; P Leger; D Veale; B Langevin; D Robert; P Lévy
Journal:  Chest       Date:  1995-02       Impact factor: 9.410

View more
  8 in total

Review 1.  The effect of nasal surgery on continuous positive airway pressure device use and therapeutic treatment pressures: a systematic review and meta-analysis.

Authors:  Macario Camacho; Muhammad Riaz; Robson Capasso; Chad M Ruoff; Christian Guilleminault; Clete A Kushida; Victor Certal
Journal:  Sleep       Date:  2015-02-01       Impact factor: 5.849

2.  The benefit of HH during the CPAP titration in the cool sleeping environment.

Authors:  Yayong Li; Yina Wang
Journal:  Sleep Breath       Date:  2016-05-18       Impact factor: 2.816

3.  The effects of heated humidifier in continuous positive airway pressure titration.

Authors:  Chung-Chieh Yu; Cheng-Ming Luo; Yu-Chih Liu; Huang-Pin Wu
Journal:  Sleep Breath       Date:  2012-02-04       Impact factor: 2.816

4.  Selective indication for positive airway pressure (PAP) in sleep-related breathing disorders with obstruction.

Authors:  Norbert Stasche
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2006-10-05

5.  A pilot study of an in-vitro bovine trachea model of the effect of continuous positive airway pressure breathing on airway surface liquid.

Authors:  David E White; Roy J Nates; Jim Bartley
Journal:  Biomed Eng Online       Date:  2014-02-06       Impact factor: 2.819

6.  Compliance with continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea among privately paying patients- a cross sectional study.

Authors:  Syed Fayyaz Hussain; Muhammad Irfan; Zeeshan Waheed; Naveen Alam; Saba Mansoor; Muhammad Islam
Journal:  BMC Pulm Med       Date:  2014-11-29       Impact factor: 3.317

7.  Initial adherence to autotitrating positive airway pressure therapy: influence of upper airway narrowing.

Authors:  Yoon Kyoung So; Hun-Jong Dhong; Hyo Yeol Kim; Seung-Kyu Chung; Jeon-Yeob Jang
Journal:  Clin Exp Otorhinolaryngol       Date:  2009-12-31       Impact factor: 3.372

Review 8.  Rhinitis and sleep apnea.

Authors:  Maria T Staevska; Mariana A Mandajieva; Vasil D Dimitrov
Journal:  Curr Allergy Asthma Rep       Date:  2004-05       Impact factor: 4.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.